Figure 2.

Validation experiments reveal inhibition of Ct growth across various serovars

(A) Schematic of the compound sets used in this study and the sequential screening steps applied to obtain a selection of a final set of 3 drugs for in vivo experiments.

(B) Dose-response curves for the 20 compounds remaining after the validation conditions. 3-fold dilutions in technical duplicates starting from 13.5 μM for Ct serovars E, F, and L2 were assessed. POC, percentage of DMSO-treated control.

(C) Representative images of indicated compounds in 13.5 μM concentration (PerkinElmer Operetta high-content automated confocal microscope, 20× long field WD); scale bars, 100 μm.